Neoplasms, Germ Cell and Embryonal × Clear all
NCT05092451 2026-03-18

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
NCT03911388 2026-02-17

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
24 enrolled
NCT01625351 2026-02-06

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

St. Jude Children's Research Hospital

Phase 1 Completed
23 enrolled
NCT04185038 2025-12-15

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Seattle Children's Hospital

Phase 1 Recruiting
90 enrolled
NCT03618381 2025-11-20

EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

Phase 1 Active not recruiting
44 enrolled
NCT04483778 2025-11-20

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Seattle Children's Hospital

Phase 1 Active not recruiting
68 enrolled
NCT02162732 2025-11-03

Molecular-Guided Therapy for Childhood Cancer

Milton S. Hershey Medical Center

Phase NA Completed
186 enrolled 12 charts
NCT04897321 2025-10-24

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

Phase 1 Recruiting
32 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
NCT03037385 2025-05-31

ARROW

Hoffmann-La Roche

Phase 1/2 Completed
590 enrolled 58 charts 5 FDA